Baker Ellis Asset Management LLC Has $1.08 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Baker Ellis Asset Management LLC decreased its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 4.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,865 shares of the company’s stock after selling 500 shares during the period. Baker Ellis Asset Management LLC’s holdings in Merck & Co., Inc. were worth $1,075,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MRK. Ruedi Wealth Management Inc. lifted its position in Merck & Co., Inc. by 180.2% in the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after acquiring an additional 200 shares in the last quarter. AlphaMark Advisors LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $34,000. Valued Wealth Advisors LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $42,000. TFO Wealth Partners LLC lifted its position in Merck & Co., Inc. by 108.1% in the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after acquiring an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new stake in Merck & Co., Inc. in the 3rd quarter valued at $50,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on MRK shares. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Truist Financial reissued a “buy” rating and set a $142.00 price target (up from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, March 27th. Finally, TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $129.71.

View Our Latest Report on MRK

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the transaction, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Merck & Co., Inc. Stock Up 0.7 %

Shares of MRK stock opened at $131.27 on Wednesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The firm’s 50-day moving average is $125.45 and its 200-day moving average is $113.20. The stock has a market cap of $332.46 billion, a price-to-earnings ratio of 931.07, a PEG ratio of 0.52 and a beta of 0.38. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same quarter in the prior year, the business earned $1.62 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.8% on a year-over-year basis. Sell-side analysts predict that Merck & Co., Inc. will post 8.59 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a $0.77 dividend. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a yield of 2.35%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 2,200.00%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.